Xenix Medical received FDA 510(k) clearance for its Riva Anchor spinopelvic fixation system.
The system is designed to facilitate fusion of the sacroiliac joint at the base of a posterior lumbar or thoracolumbar fusion construct, according to a Sept. 22 news release.
The Riva Anchor system incorporates Xenix Medical’s NanoACTIV surface technology and self-harvesting bone apertures. It is intended for use with the company’s Riva posterior fixation system and accepts 5.5- and 6.0-millimeter rods.
Xenix Medical is preparing for a limited commercial launch.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
